TA 2021 square

Tobias L Agervald


Chief Executive Officer since January 2019 and Chief Medical Officer since December 2018. Born in 1976. Dr Agervald holds an MD and PhD from Uppsala University and is a board-certified specialist in internal medicine and nephrology. Dr Agervald is an associate professor and internationally recognized researcher within experimental and clinical nephrology and endocrinology. He performed parts of his PhD studies at Harvard Medical School and a postdoctoral fellowship at Indiana University School of Medicine. Dr Agervald has extensive global drug development experience in both early and later clinical stages, most recently from his position as Senior Medical Director at Astellas Pharma Global Clinical Development.

Previous positions: Senior Medical Director at Astellas Pharma. Global key opinion leader in cardio-renal disease and frequently engaged expert for analysis of pharmaceutical development projects and design and execution of clinical studies via advisory boards and steering committees.

Other appointments:
Tobias Agervald is an adjunct associate professor at the Karolinska Institute and has been an expert consultant, lecturer or advisory board member for large pharmaceutical companies such as AbbVie, Sanofi Aventis, Genzyme, Shire, Amgen, SOBI and Astellas.

Previous assignments in the last five years:
Senior Medical Director, Astellas Pharma.

Shareholding: 1 256 977 shares and 5 200 000 employee options 2021/2026

KB 2021 square

Karin Botha


CFO since September 2020. Born 1973. Karin Botha holds a Degree of Master of Science in Business Administration and Economics and has more than 20 years of working experience from leading roles within finance in global pharmaceutical companies. Most recently as Controls and Compliance Specialist at Novartis.

Previous experience also includes positions such as Nordic Head of Financial Reporting and Accounting, Nordic Head of Business Planning and Analysis and Interim CFO.

Other engagements: board member of Matting AB

Previous assignments in the last five years: Specialist and Nordic Head of Financial Controls and Compliance at Novartis and Sandoz

Shareholding: 64 283 shares and 1 200 000 employee options 2021/2026

LO 2021 square

Lars Olsson

CMC Head

CMC Head since March 2020. Born in 1967. Lars Olsson and is responsible for the CMC-activities in the company. He holds a Ph.D. in organic chemistry and have more than 20 years of pharmaceutical development experience with projects in both early and late phase.

Previous positions. Have been CMC responsible at Wilson Therapeutics and Karo Bio and managed various CMC projects and tasks at Acadia, Medivir and AstraZeneca. Previous experiences includes development of manufacturing processes, project management of external partners, participation in clinical study teams and company management.

Other assignments: Consultancy in the CMC field.

Previous assignments in the last five years: Wilson Therapeutics, Corline Biomedical, RG Pharma Development

Shareholding: 0 shares and 875 000 employee options 2021/2026

PG 2021 square

Peter Gilmour

Head of Preclinical Science

Head of Preclinical Science since August 2020. Born in 1970. An expert in nonclinical drug discovery and developmental pharmacology, molecular biology and toxicology, Peter is responsible for all nonclinical science in Guard. He has a PhD in toxicology and more than 25 years’ experience in pharmaceutical discovery and clinical development, and drug repurposing in a variety of therapeutic areas.

His previous pharmaceutical career came from AstraZeneca and Astellas Pharma as pharmacologist in projects from discovery to regulatory filing.

Other appointments: Consultancy in nonclinical drug development

Previous appointments in the last five years: Founder of The Drug Development Team, Astellas Pharma Europe and AstraZeneca, UK.

Shareholding: 0 shares and 875 000 employee options 2021/2026

AK 2021 square

Ann-Kristin Myde

Head of Global Project Management

Head of Global Project Management since April 2021. Born 1955. She is responsible for leading global cross-functional project teams at Guard. Ann-Kristin holds a degree of Bachelor of Science in Biochemistry and has more than 30 years of working experience in the pharmaceutical industry from both large and smaller companies.

Ann-Kristin has had a number of senior positions in project management, clinical development and marketing from AstraZeneca and Thermo Fisher. Before joining Guard Therapeutics, she worked at Calliditas Therapeutics where she was leading clinical development and project management in renal medicine.

Other appointments: -

Previous assignments in the last five years: VP Clinical and Project Management at Calliditas Therapeutics AB

Shareholding: 0 shares and 875 000 employee options 2021/2026

ST 2021 square

Sara Thuresson

Head of Clinical Operations

Head of Clinical Operations since May 2021. Born 1976. Responsible for the execution of the company's clinical studies from a strategic and operational perspective.

Sara Thuresson has a Master of Science degree in biomedicine from the Karolinska Institute, has received postgraduate training in clinical drug development from Uppsala University and has been awarded the Swedish Diploma in Clinical Trials. She has more than 15 years of experience in leading multinational teams in planning, implementation and reporting of clinical studies through all development phases..

Previously, Sara Thuresson has held a number of different positions in clinical drug development at, among others, Oncopeptides, Glionova, Wilson Therapeutics, IQVIA and Medivir.

Other engagements: -

Previous assignments in the last five years: Clinical Operations Director at Oncopeptides

Shareholding: 42 855 shares and 875 000 employee options 2021/2026

MR 2021

Michael Reusch


Chief Medical Officer since January 2022. Born in 1960. Dr Reusch is a pharmacist and physician and holds an MD from Essen University in Germany.

He has more than 30 years’ global clinical drug development experience, most recently as Senior Medical Director at Astellas Pharma Global Clinical Development.

Other engagements: Michael Reusch provides consultancy in clinical development

Previous assignments in the last five years: Senior Medical Director at Astellas Pharma responsible for development of a new medicinal product in renal anemia.

Shareholding: -